Suven Pharmaceuticals Limited

As of March 31, 2025, Suven Pharmaceuticals Limited has 254.56M shares outstanding.

As of March 31, 2025, Suven Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 110.56. The price-to-sales ratio is 24.42, and the price-to-book ratio stands at 1,148.75.

As of March 31, 2025, Suven Pharmaceuticals Limited trades at an EV/EBITDA multiple of 98.69 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 24.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 98.69 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Suven Pharmaceuticals Limited trades at an EV/FCF ratio of 3,090.10, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of March 31, 2025, Suven Pharmaceuticals Limited maintains a current ratio of 2.43, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.16, indicating elevated leverage, while an interest coverage ratio of 24.11 demonstrates strong ability to service its debt obligations.

Over the twelve months ended March 31, 2025, Suven Pharmaceuticals Limited posted a return on equity (ROE) of 29.13, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.82 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.01, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 23.75, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.67 indicates how many times Suven Pharmaceuticals Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended March 31, 2025. That works out to an effective tax rate of 23.01, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

Over the twelve months ended March 31, 2025, Suven Pharmaceuticals Limited posted a gross margin of 72.25, reflecting its pricing power and cost economics. The operating margin of 24.86 and net profit margin of 22.09 provide insight into operational efficiency.

Suven Pharmaceuticals Limited's most recent stock split took place on September 25, 2020 with a 1:2 split ratio.

As of March 31, 2025, Suven Pharmaceuticals Limited has an Altman Z-Score of 15.95, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.